TEST:

GUARDANT SHIELD

''Guardant Health, Inc...announced that its FDA-approved Shield™ blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests.''

''Guardant Health, Inc...today announced the launch of the Shield™ multi-cancer detection (MCD) laboratory developed test (LDT) in multiple markets in Asia. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer.''

''Guardant Health, Inc...today announced the results of a new national survey conducted on its behalf by The Harris Poll with findings demonstrating that more than 9 out of 10 Americans ages 45 and over believe in ensuring broader coverage for blood-based colorectal cancer (CRC) screening, including new innovations like Shield™ by Guardant, a methylation partitioning cell-free DNA (mp-cfDNA) test and the first and only FDA-approved blood test for primary colorectal cancer screening.''

''Guardant Health, Inc...today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through the nationwide connectivity of Quest Diagnostics, equipping clinicians with access to blood-based screening innovation for colorectal cancer (CRC) through one of the largest diagnostic ecosystems in the United States.''

''Guardant Health, Inc...today announced its partnership with actor and cancer advocate Patrick Dempsey to increase awareness about colorectal cancer (CRC) screening and the Shield® blood test.''

P=N/A, N=297, Completed, Milton S. Hershey Medical Center | Recruiting --> Completed | N=500 --> 297

P=N/A, N=2004, Completed, Kaiser Permanente | N=400 --> 2004

P=N/A, N=500, Recruiting, Milton S. Hershey Medical Center | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025

"Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials."

"Guardant Health, Inc...today announced an agreement with the Abu Dhabi Public Health Center (ADPHC) to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational pharmaceutical group and regional partner for Guardant in the Middle East and North Africa, and will be administered by the M42 healthcare system...The Shield test will be provided as part of the ADPHC’s IFHAS comprehensive health screening program and will be available at major healthcare facilities operated by Ambulatory Healthcare Services and M42 sites across Abu Dhabi, Al Ain, and the Al Dhafra region....The blood-based colorectal cancer screening program is expected to screen approximately 10,000 people across Abu Dhabi and surrounding regions in its first year."

First-generation cf-bDNA tests may deliver net benefit or harm, depending on the balance between achieving screening in persons who decline alternatives versus substituting cf-bDNA for more effective alternatives. The Gorrindo Family Fund.

"Guardant Health, Inc...announced the company and its research collaborators will present data supporting the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening adherence at the American College of Gastroenterology (ACG) 2024 Annual Meeting in Philadelphia, Oct. 25-30, 2024. Guardant and its research partners will share real-world data demonstrating poor patient compliance with repeat stool-based screening....A second presentation will report on the one-year outcomes of individuals tested with Guardant’s Shield blood test for CRC screening in the ECLIPSE study to understand the implications of 'false positive' results."